If you purchased or acquired securities in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth? The content of this article is ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients ... the drug’s two existing approvals in China, which cover other prostate cancer patient populations.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK (LSE: GSK) has reported a 7% increase in full-year revenue ... data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free ...